A potential label for the US consumer health product industry’s January-March period might be the dismissal of a challenge to an iconic analgesic’s label and the easing of a regulatory burden for filing OTC label updates combined with the introduction of a first-ever nonprescription label.
US OTC drug and dietary supplement firms’ reports of their results for the first three months of 2024 begins on April 19 with
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?